Eledon Pharmaceuticals (ELDN)
(Delayed Data from NSDQ)
$2.78 USD
+0.06 (2.21%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $2.74 -0.04 (-1.44%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ELDN 2.78 +0.06(2.21%)
Will ELDN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ELDN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELDN
Eledon Pharmaceuticals (ELDN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Eledon Pharmaceuticals, Inc. (ELDN) is a Great Momentum Stock: Should You Buy?
ELDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Eledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade
Eledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for ELDN
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Eledon Pharmaceuticals (ELDN) and Abbott Laboratories (ABT)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Eledon Pharmaceuticals (ELDN), BioNTech SE (BNTX) and Eli Lilly & Co (LLY)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alkermes (ALKS), Eledon Pharmaceuticals (ELDN) and Legend Biotech (LEGN)
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon gives data on tegoprubart for rejection prevention in kidney transplant